MSCO | QNA

A: Triple-negative breast cancer & ER-positive disease 0%

B: Triple-negative breast cancer & Inflammatory breast cancer 0%

C: ER-positive disease & metastatic breast cancer 0%

D: Ductal carcinoma in situ & invasive ductal carcinoma 0%

Referring to speaker slide at time of presentation: 2:10.

The overview of ESMO 2020.

A: Addition of CIT significantly improves pCR in the ITT population. 0%

B: Both pCR data of Keynote 522 and Impassion 031 demonstrated better performance compared to placebo + chemo arm. 0%

C: The pCR (ypT0/Tis yp N0) result of Atezo + chemo in Impassion 031 is 57.6%. 0%

D: The pCR (ypT0/Tis yp N0) result of Placebo + chemo in Impassion 031 is 57.6%. 0%

Referring to the speaker slide at time of presentation: 8:02, the pCR (ypT0/Tis yp N0) result of Placebo + chemo in Impassion 031 is 41.1%.

A: Atezolizumab + Nab-Paclitaxel improves PFS & OS in 1st line mTNBC 0%

B: Combinations well tolerated 0%

C: Pembrolizumab + Taxanes or Gem/Carboplatin improves OS in 1st line mTNBC 0%

D: Effect largely limited to PD-L1 + tumors (SP142 - Atezo; CPS10 - Pembro) 0%

Referring to the speaker slide at time of presentation: 18:51.

About the summary of CIT in metastatic TNBC.

A: Fatigue 0%

B: Diarrhea 0%

C: Leukopenia 0%

D: IRR 0%

Referring to the speaker slide at time of presentation: 26:00.

About the treatment-Emergent Adverse Events.

A: 4.8% 0%

B: 6.3% 0%

C: 8.9% 0%

D: 12.2% 0%

Referring to the speaker slide at time of presentation: 26:18.

About the diarrhea over time graph.